

1 **The evolution of dengue-2 viruses in Malindi, Kenya and greater East Africa: epidemiological and**  
2 **immunological implications**

3 S Pollett<sup>1</sup>, K Gathii<sup>2</sup>, K Figueroa<sup>1</sup>, W Rutvisuttinunt<sup>1</sup>, A Srikanth<sup>1</sup>, JN Nyataya<sup>2</sup>, BK Mutai<sup>2</sup>, G Awinda<sup>2</sup>, RG  
4 Jarman<sup>1</sup>, I Maljkovic Berry<sup>1\*#</sup>, JN Waitumbi<sup>2\*</sup>

5 <sup>1</sup>Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland

6 <sup>2</sup>Basic Science Laboratory, US Army Medical Research Directorate – Africa (USAMRD-A), Kisumu, Kenya

7 \*Contributed equally to this study

8 #Corresponding author

9 **Abstract**

10 Kenya experiences a substantial burden of dengue, yet there are very few DENV-2 sequence data  
11 available from this country and indeed the entire continent of Africa. We therefore undertook whole  
12 genome sequencing and evolutionary analysis of fourteen dengue virus (DENV)-2 strains sampled from  
13 Malindi sub-County Hospital during the 2017 DENV-2 outbreak in the Kenyan coast. We further  
14 performed an extended East African phylogenetic analysis, which leveraged 26 complete African *env*  
15 genes. Maximum likelihood analysis showed that the 2017 outbreak was due to the Cosmopolitan  
16 genotype, indicating that this has been the only confirmed human DENV-2 genotype circulating in  
17 Africa to date. Phylogeographic analyses indicated transmission of DENV-2 viruses between East Africa  
18 and South/South-West Asia. Time-scaled genealogies show that DENV-2 viruses are spatially structured  
19 within Kenya, with a time-to-most-common-recent ancestor analysis indicating that these DENV-2  
20 strains were circulating for up to 5.38 years in Kenya before detection in the 2017 Malindi outbreak.

21 Selection pressure analyses indicated sampled Kenyan DENV strains uniquely being under positive  
22 selection at 6 sites, predominantly across the non-structural genes, and epitope prediction analyses  
23 showed that one of these sites corresponds to a putative predicted MHC-I CD8+ DENV-2 Cosmopolitan  
24 virus epitope only evident in a sampled Kenyan virus. Taken together, our findings indicate that the  
25 2017 Malindi DENV-2 outbreak arose from a strain which had circulated for several years in Kenya  
26 before recent detection, has experienced diversifying selection pressure, and may contain new  
27 putative immunogens relevant to vaccine design. These findings prompt further genomic  
28 epidemiology studies in this and other Kenyan locations to further elucidate the transmission dynamics  
29 of DENV in this region.

30 **Author summary (non-technical):**

31 Kenya experiences a substantial burden of dengue, yet the patterns of dengue spread in this region are  
32 unclear. Evolutionary analyses of dengue virus strain sequences could offer major insights into the  
33 spread of dengue viruses in this region, but there are very few DENV-2 sequence data available from  
34 this country and indeed the entire continent of Africa. We therefore undertook whole genome  
35 sequencing and evolutionary analysis of fourteen dengue virus (DENV)-2 strains sampled from Malindi  
36 sub-County Hospital during the 2017 DENV-2 outbreak in the Kenyan coast. We further performed an  
37 extended East African phylogenetic analysis, which leveraged 26 complete African *env* genes. Our  
38 results indicated transmission of DENV-2 viruses between East Africa and South/South-West Asia, that  
39 there is localized spread of DENV-2 viruses within Kenya, and that Kenyan DENV-2 strains were  
40 circulating for up to 5.38 years in Kenya before detection in the 2017 Coastal outbreak. We further

41 performed selection pressure analyses and identified possible new markers of DENV-2 immune  
42 recognition specific to this population, with relevance to vaccine design.

43

44 **Key words:** dengue, dengue virus, Africa, Kenya, epitopes, phylogenomics

45 **Short title:** The evolution of dengue-2 viruses in Malindi, Kenya and greater East Africa

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60 **Introduction:**

61 Dengue poses a persistent and ongoing threat to public health in many tropical countries, with an  
62 estimated global burden exceeding half a billion infections per year [1]. In hyper-endemic countries,  
63 the annual force-of-infection is 5-10%, resulting in the majority of the population exposed by  
64 adulthood [2, 3]. Non- or pauci-immune populations may also experience intermitted outbreaks with  
65 attack rates exceeding 50% [4]. In addition to an increased number of dengue endemic countries in  
66 the last three decades, some dengue hyperendemic countries have seen up to a 500% increase in  
67 dengue mortality over a 15 year period [5]. Dengue is caused by a serogroup of four dengue viruses  
68 (DENV). These are single positive-strand RNA viruses that belong to the *Flaviviridae* family, and are  
69 borne most effectively by the *Aedes aegypti* mosquito [6]. The escalating burden of dengue is in part  
70 due to the rapid urbanization of tropical regions, and in part due to the incomplete cross protection  
71 offered by a primary dengue infection [7]. Current countermeasures for dengue include vector control  
72 and optimized medical management following established guidelines. There is currently only one  
73 licensed dengue vaccine (Dengvaxia), which has been implemented in Brazil and the Philippines, and  
74 has major safety and effectiveness concerns in dengue unexposed populations [8].

75 East Africa is thought to have played a key role in the global spread of DENV in the 18th century, with  
76 apparent dengue case reports described there as early as 1823. There is a popular – but unproven -  
77 hypothesis that dengue was introduced into the Caribbean from East Africa [9, 10]. Indeed, the very  
78 term ‘dengue’, is believed to have been derived from the Swahili language (then called ‘dinga’) [10].

79 However, compared to other tropical areas, the epidemiology of dengue in East Africa, and Africa in  
80 general, is not well understood [7]. This is attributed to limited surveillance and limited availability of  
81 diagnostics for dengue, a disease that often has similar clinical symptoms and signs as other endemic  
82 tropical diseases in Africa, such as malaria [11, 12]. Further, there are immense competing public  
83 health demands in many countries from this region [12]. Nevertheless, the burden of dengue in East  
84 Africa is being increasingly recognized. Studies have indicated the circulation of DENV in Kenya as well  
85 as Djibouti, Eritrea, Ethiopia, Mozambique, Somalia, Sudan, Tanzania, and Uganda [9, 13-18].

86  
87 Kenya, in particular, has experienced substantial DENV outbreaks in coastal regions since at least 1982  
88 when DENV-2 was first detected in the towns of Malindi and Kilifi [19, 20]. Since the initial detection in  
89 the early 1980s, a substantial DENV-2 outbreak occurred in the North-Eastern town of Mandera in  
90 2011, which was thought to be introduced from Somalia based on its proximity to the Kenyan border  
91 [21]. A substantial DENV outbreak was noted in the urban Mombasa in 2013, with an attack rate of  
92 approximately 13% in one district alone [22]. Extended dengue testing on febrile cases presenting to a  
93 range of hospitals throughout Kenya in 2011-2014 also indicated the circulation of DENV serotypes 1 -  
94 3 in the coastal locations of Mombasa, Malindi and Lamu, the North-Eastern locales of Garissa and  
95 Wajir, and the Western capital of Nairobi [23]. More recently, through molecular characterization of  
96 undifferentiated febrile cases, DENV 1 -4 was detected in a 2014 - 2015 pediatric febrile surveillance  
97 cohort in Western Kenya (Chulaimbo and Kisumu), although it remains unclear why dengue outbreaks  
98 are more frequently noted on the Kenyan coast [24].

99

100 The population seroprevalence of DENV in Kenya is highest in coastal regions, where DENV  
101 seropositivity has exceeded 58.8% across all ages tested, and has exceeded 20% in the under ten year  
102 olds [25]. Western Kenyan seroprevalence is estimated to be considerably lower, although still  
103 substantial in pediatric age strata, suggesting inter-epidemic transmissions occurs in both Western and  
104 Coastal Kenya [26]. *Aedes aegypti* is prevalent in both coastal Kenya as well as more Western regions,  
105 including the Kisumu and the capital Nairobi [12, 27-29]. Ecological and demographic changes, such as  
106 increasing irrigation farming, international travel, and urbanization, are believed to be risk factors for  
107 ongoing dengue outbreaks in this country [12, 22, 30].

108

109 Despite the increasingly recognized burden of DENV in Kenya, there has been few DENV sequence data  
110 published from this country. The 2011-2014 Mombasa outbreak yielded short partial *env* sequences,  
111 which only permitted genotyping [23]. The paucity of sequence data from Kenya has limited our  
112 understanding of the epidemic dynamics of recent Kenyan DENV outbreaks. Further, there is a lack of  
113 DENV African genomic data in general. A recent comprehensive assessment of the global adequacy of  
114 dengue genetic sampling indicated that Africa represents just 1% of all published DENV full *env*  
115 sequence data [31]. In the case of DENV-2, there are very few African-sampled whole genome DENV-2  
116 sequences published. This lack of African DENV sequence data has long confounded attempts to  
117 elucidate the role of East Africa in global DENV spread, and has limited any inference about whether  
118 recently developed and/or licensed dengue vaccine products may be mismatched to circulating dengue  
119 viruses in Africa [32-34].

120

121 To redress this dearth of Kenyan DENV genomic data, and to investigate a recent Kenyan DENV-2  
122 outbreak within a phylodynamic framework, we undertook whole genome sequencing and  
123 evolutionary analysis of 14 DENV-2 whole genomes. These data represent a major increase to the  
124 previously available number of African DENV-2 whole genome data. Specifically, we sought to estimate  
125 the duration of cryptic circulation of DENV-2 before first case detections in the 2017 in Malindi  
126 outbreak and determine whether this outbreak could be partly explained by viral immune escape.  
127 Leveraging these new data and all existing public DENV data, we also performed an extended regional  
128 East African molecular epidemiology of 26 complete African *env* genes to offer insight into dispersal  
129 and population structure of DENV-2 viruses in East Africa relative to other African and other global  
130 regions. In order to support future vaccine development and evaluation, we further explored whether  
131 there were any novel T cell epitopes identified along the DENV-2 whole proteome relevant to the  
132 Kenyan population.

### 133 **Methods:**

#### 134 *Field methods: study population, setting and dengue case detection*

135 The coastal city of Malindi, Kenya, is located 120 kilometers Northeast of Mombasa, a major urban  
136 seaport of Kenya. Malindi is the largest urban area of Kilifi County, with a population of 207,000  
137 persons [35], and is known to be endemic for dengue [23]. Patients with suspected dengue cases  
138 presenting to Malindi sub-county Hospital, Malindi, Kilifi County in 2017 for clinical care were  
139 consented under an IRB approved protocol that recruits patients with acute febrile illness. Dengue  
140 infections were confirmed in 14 suspect cases by genotyping using EasyScreen flavivirus PCR typing kit  
141 (Genetic Signatures, Australia).

142 *RNA extraction and sequencing methods at the Basic Science Lab (Walter Reed Project/KEMRI, Kisumu,*  
143 *Kenya):*

144 From the 14 confirmed DENV-2 infections, RNA extraction and sequencing was performed at the Basic  
145 Science Lab (KEMRI, Kisumu, Kenya as recently described by Gathii et al [19]. Briefly, total RNA was  
146 extracted from the sera using the Direct-zol miniprep kit (Zymo Research). cDNA synthesis was  
147 performed by sequence-independent single-primer amplification following methods by Djikeng et al  
148 [36], followed by cDNA amplification using MyTaq DNA polymerase (Bioline, MA). The Nextera XT kit  
149 (Illumina, San Diego, CA) was used to prepare sequence libraries before sequencing on the MiSeq  
150 platform (Illumina, San Diego, CA). Their sequence data underwent assembly and annotation using CLC  
151 Genomics Workbench version 8.5.1 (Qiagen), using a DENV-2 reference genome (GenBank accession  
152 number: NC001474). Whole genome sequences were derived from 10 of the 14 specimens (GenBank  
153 accession numbers: MG779194 - MG779203).

154 *RNA extraction and sequencing methods at the Department of Virology (WRAIR):*

155 Extracted RNA from an additional four DENV-2 infected sera that failed to sequence in Kenya  
156 underwent DENV-2 whole genome sequencing at the Walter Reed Army Institute of Research using in-  
157 house designed primers which were optimized to the Kenyan DENV-2 sequence data generated by  
158 Gathii et al. Amplicons were generated from extracted RNA by these DENV-2 specific primers in  
159 addition to random primers. A conventional amplification using DENV-2 specific primers (Table S1)  
160 were generated with Taq polymerase (ThermoFisher, Waltham, MA). Random amplicons were  
161 obtained using SuperScript III RT and HiFi Taq (ThermoFisher, Waltham, MA). Enhanced sensitivity in  
162 amplification was pursued utilizing microfluidic amplification with DENV-2 specific and random primers



163 and SSIII/HiFi Platinum Taq on the integrated fluidic circuits (IFC) (Fluidigm, Palo Alto, CA). The reaction  
164 conditions for both conventional and microfluidic amplifications were 50°C for 30 minutes and 94°C for  
165 2 minutes followed by 35 cycles of 94°C (30 seconds), 55°C (30 seconds), and 68°C (2 minutes), and a  
166 hold at 68°C for 7 minutes prior to cooling down to 4°C. Amplicons were used for NexteraXT libraries  
167 (Illumina, San Diego, CA) and QIASeq Fx libraries (QIAGEN, Germantown, MD). Libraries were validated  
168 using Qubit (ThermoFisher, Waltham, MA) and TapeStation (Agilent, Santa Clara, CA). The sequencing  
169 was conducted on the MiSeq reagent v.3 600 cycles (Illumina, San Diego, CA). The four genomes were  
170 assembled using ngs\_mapper v1.5, an in-house reference mapping pipeline [37], and curated manually  
171 for removal of sequencing and assembly-associated errors. Ngs\_mapper output files, VCF, BAM and  
172 statistical read quality/depth graphs, were used to support base-call curations. Pipeline parameters,  
173 minimum base quality and allele frequency thresholds, were kept at respective defaults of Q25 and  
174 20% for consensus sequence reconstruction. The accession number of these genomes sequenced at  
175 WRAIR were MN335244-MN335247.

#### 176 Evolutionary analysis:

##### 177 *Genotyping, recombination detection and phylogenomic analysis 14 Kenyan DENV strains:*

178 All 14 full genome sequences (including the 10 full genomes recently reported by Gathii et al) were  
179 collated with a comprehensive curated reference dataset of 1212 published annotated whole genome  
180 DENV-2 data available on the VIPR and NCBI Genbank databases as of April 2018 [38, 39] (Table S2).  
181 Alignment was performed using MAFFT and manually edited thereafter, before truncation to coding  
182 regions [40]. Initial neighbor-joining trees were used to confirm the genotype of these data as the  
183 Cosmopolitan lineage using MEGA version 7.0 [41]. Thereafter, we inferred a maximum likelihood tree

184 using all new Kenyan whole genome data, all published Cosmopolitan lineage whole genome data (n =  
185 274), and an American genotype outgroup strain (GenBank accession number HM582104). This dataset  
186 included the three African DENV-2 Cosmopolitan genomes available at the time of GenBank search,  
187 including n = 1 from Tanzania, n = 2 from Burkina Faso. Notably, this whole genome analysis excludes  
188 the 200 nt partial env-gene sequences derived from the 2011-2014 Mombasa outbreak [23], as such  
189 short sequence lengths lack appropriate phylogenetic resolution. We screened for recombinants using  
190 the RDP4 program [42], as well as screening for incongruences in neighbor-joining trees of four  
191 subgenomic regions (CDS nucleotide positions 1-2543, 2544-5087, 5088-7630 and 7631-10173)  
192 inferred using MEGA 7.0. We removed those sequences with suspected recombination. A final  
193 maximum likelihood phylogeny was inferred using the PhyML software using the NNI and SPI tree  
194 search method and the aLRT approach for node support [43]. A GTR+I+G nucleotide substitution model  
195 was selected by Akaike information criterion (AIC) criteria using JModelTest2 [44].

196 *East African molecular epidemiology analysis leveraging an extended env-gene dataset:*

197 Due to major whole genome sampling gaps in Kenya, and indeed throughout Africa, we also inferred  
198 an env-gene tree, including more sequences, to estimate the regional and international  
199 phylogeography of DENV-2 in East Africa. This leveraged an extended Cosmopolitan genotype  
200 complete env-gene alignment (Table S3) containing n = 1343 complete env sequences, including all  
201 African full-length env sequence data available at the time of GenBank search (n = 26 total, including  
202 Burkina Faso n = 4, Somalia n = 6, Tanzania n = 1, Uganda n = 1 and the Kenyan data from this study n =  
203 14). We inferred a maximum likelihood tree using the PhyML software, with a GTR+I+G nucleotide  
204 substitution model selected by AIC in jModelTest2 [44].

205 *Time-scaled Bayesian phylogeographic analyses to reconstruct the history of the Kenyan 2017 DENV*  
206 *outbreak:*

207 All 14 genomes were analyzed using Bayesian phylogeography to further clarify the time-scale and  
208 rates of Kenyan DENV virus evolution. A whole-genome time-scaled phylogeny was inferred using the  
209 BEAST package [45]. Given the large computational load of performing Bayesian analyses on a large  
210 serotype-wide full-genome dataset, we restricted the analysis to strains comprising the basal  
211 sublineage of the Cosmopolitan genotype which contained all Malindi Kenyan data (Fig 1). Root-to-tip  
212 regression was performed using Temp-est which indicated adequate temporal structure of this  
213 subsampled data (coefficient of determination = 0.91,  $n = 37$  sequences). Time-scaled Bayesian  
214 analysis was performed using a nucleotide model of SYM+I+G as selected using AIC criteria in  
215 jModelTest2. A maximum clade credibility tree was inferred using the posterior distribution of 10,000  
216 trees sampled from a 200 million Markov Chain under a relaxed clock assumption (uncorrelated  
217 lognormal distribution) and a skyline demographic model. Statistical convergence was determined by  
218 examining trace plots in addition to ESS values, which exceeded 200 for all parameters.

219 *Selection pressure analysis:*

220 We estimated gene-wide and site-specific selection pressure across the entire genome of all Malindi  
221 Kenyan and publicly available unique DENV-2 Cosmopolitan strains in addition to a single American  
222 genotype outgroup strain ( $n = 275$  taxa). The SLAC, FUBAR and FEL methods available in the HyPhy  
223 package were employed [46, 47]. We used multiple selection pressure detection methods as they  
224 substantially vary in sensitivity and specificity [7]. The computational demand of selection pressure  
225 analysis across a whole genome dataset of this size required separate analyses on three partitions of

226 the DENV-2 genome: the structural genes (C-prM-env), non-structural genes NS1 through NS3, and  
227 non-structural genes NS4 & NS5.

228 *MHC-I CD8+ epitope prediction within DENV-2 Cosmopolitan proteomes from Kenya and beyond*

229 CTL (Cytotoxic T cell Lymphocyte) epitope discovery, particularly in critically under-sampled regions like  
230 Africa, has major relevance for dengue vaccine development and evaluation. These Kenyan data,  
231 compiled with a comprehensive global DENV-2 Cosmopolitan genotype curated dataset, allowed us to  
232 examine whether strains from this global region may contain possible novel CTL epitopes. We first  
233 predicted the HLA MHC-I haplotypes of the hosts sampled in this study using a population genetics  
234 framework, which leveraged the curated [www.allelefrequencies.net](http://www.allelefrequencies.net) database. The C\*06:02, C\*04:01  
235 and A\*02:01 alleles were selected based on their relatively high prevalence across all published Kenyan  
236 HLA admixture studies and because they are considered to be relatively frequent alleles in the global  
237 human population [48]. Further, the HLA A\*02 haplotype is an HLA super-type with high MHC-I cross  
238 reactivity [49].

239 Using these selected HLA molecules we performed MHC-I affinity prediction across sequential 9mer  
240 peptides across the entire DENV-2 proteome of all Kenyan whole genome data using the Artificial  
241 Neural Network method [50]. We then determined whether any of these predicted 9mer peptides  
242 correspond to previously *in-vitro* studied linear CD8+ or CD4+ epitopes in the IEDB database [51].  
243 Finally, we performed a conservancy analysis of these 9mer peptides to determine whether such  
244 putative epitopes are possibly geographically restricted.

245 *Ethics:*

246 Field methods, laboratory and viral genomic analyses of dengue positive cases was performed in  
247 concordance with the Ethical Review Committee of the Kenya Medical Research Institute (SSC protocol  
248 #1282) as well as the Human Subject Protection Branch of the Walter Reed Army Research Institute  
249 (WRAIR protocol #1402). All participants gave informed consent. A parent or guardian of any child  
250 participant provided informed consent on the child's behalf. In addition, children between 13 and <18  
251 years provided assent to participate. Consent was written if participant was literate and fingerprint if  
252 illiterate, with the signature of an independent witness.

### 253 **Results:**

#### 254 *Clinical and demographic characteristics:*

255 All the 14 patients from whom the whole DENV genome sequences were derived were recruited in the  
256 months of April to June 2017. All had typical signs of dengue fever comprising high fever (>38.5 °C),  
257 headache, chills, muscle and joint pains and body rash.

#### 258 *Kenyan DENV-2 belongs to the Cosmopolitan genotype and there is no evidence of DENV-2* 259 *recombinants circulating in Kenya*

260 Genotype determination showed that these DENV-2 strains sampled from Kenya, and indeed all other  
261 East African countries sampled to date, are of the Cosmopolitan genotype. None of the Kenyan  
262 genomes were found to be recombinant, although there was significant ( $p < 0.05$ ) recombination signal  
263 detected in a Sri Lanka genome (accession number: FJ882602) by 2 of 7 methods used in RDP4 (RDP  
264 and BootScan), indicating a ~700bp insert from a parental genome detected to be  
265 Pakistan\_Karachi/2008 (accession number: KF041236). As this constitutes borderline evidence of

266 recombination, we further tested for phylogenetic incongruence by dividing the full genome alignment  
267 into 4 equal length alignments. NJ phylogenetic trees (Fig S1) were constructed for each part of the  
268 genome to assess changes in tree topology along the genome, which was indeed noted. Because  
269 phylogenetic inference is affected by recombination, the Sri Lanka 2008 genome was removed from  
270 the alignment [7]. This approach also identified that the position of the two Burkina Faso human  
271 cosmopolitan strains (accession numbers: EU056810, GU131843), and a further five Indonesian whole  
272 genomes (accession numbers: GQ398260, GQ398261, GQ398262, GQ398258, GQ298259) also changed  
273 between phylogenetic trees inferred across the DENV2 genome, and these were also removed as  
274 possible recombinants (Fig S1).

275

276 *East African DENV2 Cosmopolitan viruses endemically circulate, but there is evidence of transmissions*  
277 *between East Africa and Asia*

278 Kenyan genomes from Malindi cases were found in a monophyletic, well supported cluster separated  
279 from other African and international genomes in the sub-lineage with a long branch (Fig 1), indicating  
280 national-scale spatial structure of Kenyan populations and endemic circulation. They were most closely  
281 related to whole genome viruses from Pakistan and India (Fig 1), suggestive of dispersal between  
282 South/South-West Asia and East Africa. However, this result must be cautiously interpreted given the  
283 long branch ancestral to the Kenyan cluster, consistent with the very limited whole genome sampling  
284 of DENV-2 in other African countries, and elsewhere in Kenya. The *env*-gene phylogeny contained more  
285 African sequences from Burkina Faso, Ghana, Tanzania, Uganda and Somalia improving the resolution  
286 of DENV-2 Cosmopolitan in this region (Fig 2). This phylogeny indicates that DENV-2 Kenya African  
287 viruses were most closely related to Indian strains (Fig 2), although the branch length of the Kenyan

288 clade was still long even in the *env* tree. The sole Uganda strain also clustered with Indian sequences,  
289 but its poor branch support also includes the possibility of previous transmissions between Kenya and  
290 Uganda (Fig 2). This extended *env* analysis also indicated that the strains from the 2011 Somalia  
291 outbreak were not ancestral to the sampled 2017 Kenya strains. Indeed, these were positioned into an  
292 entirely separate clade which included strains from Burkina Faso and Ghana and which comprised an  
293 “East-West” African cluster sampled over 28 years, indicating long term endemic African circulation of  
294 the DENV-2 Cosmopolitan genotype. Interestingly, this East-West cluster suggested spread between  
295 Africa and Saudi Arabia (Fig 2). Asian-African transmission was also inferred in the well supported  
296 clustering of a Tanzanian strain in a Chinese clade (Fig 2).

297 Given the regional importance of this “East-West” African cluster, we performed an extended time-  
298 scaled Bayesian analysis in BEAST to estimate the geographic history of this endemic DENV-2 lineage,  
299 the methodological details of which are indicated in the supplemental Box S1. A maximum clade  
300 credibility tree confirmed that Burkina Faso seeded neighboring Ghana outbreaks in 2005, and  
301 indicated a high probability of transmission of DENV-2 from Africa into neighboring Saudi Arabia (Fig 3).  
302 This same analysis estimated that this lineage of DENV-2 emerged in Somalia and Burkina Faso as early  
303 as 1978 (TMCRA 1981, 95% HPD 1978-1983) and 1978 (TMRCA 1980, 95% HPD 1977-1982),  
304 respectively. The dated root the East-West cluster indicated emergence of this DENV-2 strain in Africa  
305 as early as 1975 (TMRCA 1978, 95% HPD 1975-1981). The exact origins of this strain remains unclear,  
306 with only moderate probability support for Burkina Faso as the country of emergence (Fig 3),  
307 suggesting that other unsampled African or non-African countries may have played a key role of the  
308 early epidemic history of this East-West sublineage.

309 *The current 2016-2017 DENV2 outbreak into Malindi arose from strains introduced in 2013*

310

311 There was weak evidence only (probability = 0.55) that the recent DENV-2 Cosmopolitan Kenyan clade  
312 was originally introduced from India, and this poor statistical support primarily reflects geographic and  
313 temporal sampling gaps in Africa (Fig 4). The time-to-most-common-recent-ancestor of the node which  
314 defined all Kenyan Malindi DENV-2 Cosmopolitan strains was estimated at September 2013 (95%  
315 credible interval January 2012 – May 2015), thereby indicating that this particular DENV clade has been  
316 circulating in Kenya for approximately 3.72 years (2.06 – 5.38 years) (Fig 4), although such an estimate  
317 is limited by a paucity of data sampled from other Kenyan locales. This Bayesian analysis estimated the  
318 mean evolutionary rate of the entire Cosmopolitan sub-lineage to be  $8.94 \times 10^{-4}$  subs/site/year (95%  
319 credible interval  $5.7 \times 10^{-4}$  to  $1.28 \times 10^{-3}$ ), which is comparable to other estimates of DENV-2  
320 evolutionary rates [7]. We further showed that there was considerable variability in strain evolutionary  
321 rate across this entire Cosmopolitan sub-lineage (coefficient of variation = 0.56, 95% credible interval  
322 0.31 – 0.89) supporting a relaxed molecular clock model. Indeed, there was greater than three-fold  
323 variability in the evolutionary rates of the ancestral strains of the Kenyan outbreak alone (range  $5 \times 10^{-4}$   
324 through to  $1.8 \times 10^{-3}$  substitutions/site/year). Analysis at this spatial scale also indicated that the  
325 Kenyan cluster separates into at least two well defined clades with strain co-circulation even at this  
326 fine spatial scale, although it is unclear if this represents two distinct introductions of two strains or *in-*  
327 *situ* diversification of a single introduced strain (Fig 4).

328 *Positive selection and immune escape may explain epidemic diversification during the 2017 DENV-2*

329 *Kenyan outbreak*



330 Table 1 shows the codons along the entire genome of the whole DENV-2 Cosmopolitan lineage which  
331 are estimated to be under positive selection, and most of these were found on the non-structural  
332 genes. Of these seven codon locations, there was strong evidence (positive by three methods) for  
333 diversifying selection pressure at codon 1867 which is located in the NS3 gene, and codon 2762 in the  
334 NS5 gene. In addition to the above analyses of the Cosmopolitan lineage as a whole, the FEL approach  
335 can be used to compare different selection pressures within specific sub-lineages or clades within the  
336 dataset (Table 2). Thus, Kenyan clade was selected to be used as the sub-dataset for selection analyses  
337 and compared to the rest of the Cosmopolitan lineage which was set as the background dataset.  
338 Whole genome selection pressure analyses of the Kenyan clade alone revealed presence of  
339 positive/diversifying selection that was acting on the Kenyan genomes only (Table 2), although this  
340 finding is derived from one selection pressure method only.

341 *Extended Kenyan genome data reveals a possible novel MHC-I CD8+ epitope within the DENV-2*  
342 *Cosmopolitan lineage*

343 Through our CTL prediction analyses, we identified seven possible CTL epitopes across the Kenyan data  
344 (Table 3), the majority across the non-structural proteins. Only three of these have had previous  
345 experimental data to support their role as possible CD8+ CTL epitopes and/or CD4+ T-helper cell  
346 epitopes (FRKEIGRML, GWGNGCGLF and FTMRLSPV). While the FRKEIGRML and GWGNGCGLF  
347 peptides are highly conserved across all existing published global DENV-2 Cosmopolitan whole genome  
348 data, FTMRLSPV appears to be more geographically restricted to DENV viral populations in South Asia,  
349 South West Asia and Kenya (Table 3). Of the four potential novel epitopes, KMDIGAPLL was not found  
350 in any sampled non-Kenyan viral populations suggesting that there may be unique DENV CTL epitopes

351 in those strains circulating Kenya. A position within the TFDSEYIKT epitope was found to be under  
352 positive selection for the Cosmopolitan lineage as a whole (Table 1), suggesting that this may be a  
353 substantial immunogen. Interestingly, one of the predicted CD8+ epitopes, FRKEIGRML in the capsid  
354 region, was found within a linear epitope associated with MHC-II positive assays, suggesting that this  
355 specific region may have high immunogenicity for development of both CD4+ and CTL responses to  
356 DENV2.

### 357 **Discussion:**

358 Prior to this study, there were a very limited number DENV-2 whole genomes were available from the  
359 entire continent of Africa. Our study enabled insights into the spatial structure of DENV-2 viruses in  
360 Africa. We show transmissions between Africa and Asia, as well as evidence of long term circulation of  
361 DENV-2 viruses in Africa with related lineages that span the geographic breadth of the continent and  
362 which may have emerged as early as the 1970s. Our analyses are in line with previous reports of  
363 Cosmopolitan lineage being the only DENV2 lineage found in Africa to date, however this may simply  
364 reflect under-sampling of DENV-2 in Africa. Indeed, the apparent sole circulation of the Cosmopolitan  
365 genotype is unusual given that other DENV-2 endemic continents, such as Asia, have experienced up to  
366 four other genotypes [31]. A study recently reported a DENV-2 Asian-II genotype strain isolated from  
367 West Africa, however the implausible lack of evolution for its sampling date rather indicates that this  
368 sample actually represents a New Guinea C 1944 contaminant [52].

369 We showed spatial structure to African DENV-2 epidemics on several scales. On an intercontinental  
370 scale we show evidence of DENV-2 dispersal between East Africa and proximal South-West Asia (Saudi  
371 Arabia). Within Africa, there was evidence of DENV-2 spread on an East-West axis, and high probability

372 of spread between neighboring Burkina Faso and Ghana. Interestingly, our analysis suggests that the  
373 recent Kenyan 2017 DENV-2 outbreak was unrelated to the 2011 DENV outbreak in neighboring  
374 Somalia, highlighting the utility of genomic epidemiology in evaluating the origins of DENV outbreaks.  
375 Time-scaled genealogies indicate that DENV-2 viruses are also spatially structured within Kenya, with a  
376 time-to-most-common-recent ancestor analysis indicating that DENV-2 strains were circulating for up  
377 to 5.38 years in Kenya before detection in the 2017 Malindi outbreak, although such estimates are  
378 subject to unsampled viruses from other Kenyan locations. This estimate of pre-outbreak circulation  
379 time highlights that DENV strains may circulate in a population for years before detection by sentinel  
380 surveillance mechanisms. Indeed, this has been shown in other DENV endemic tropical countries, such  
381 as Singapore [53]. Our analyses also indicated that there was spatial structure of dengue viruses at a  
382 subnational scale, with two co-circulating clades detected within Malindi. Such fine-scale co-circulation  
383 of within-genotype clades has also been noted in other tropical dengue-endemic regions such as  
384 Thailand [54]. A caveat to these spatial epidemiological conclusions is that they are susceptible to  
385 unsampled dengue viruses elsewhere in Kenya and neighboring regions. The influence of missing data  
386 on phylogeographic conclusions is well known [7], and further sampling in complementary genomic  
387 epidemiology studies from this country will be critical to clarify the epidemiology of DENV-2 in the  
388 Coastal Kenyan and greater East African region.

389 Selection pressure analyses indicated Kenyan DENV strains uniquely being under positive selection,  
390 predominantly across the nonstructural genes, which may reflect population immunity escape  
391 associated with the 2016-2017 outbreak viral variants, and which may predict epidemic diversification  
392 of these strains among other Kenyan populations. A caveat to this is that selection pressure analyses  
393 are best confirmed with a least three independent methods, yet such methods in this case do not allow

394 the direct comparison of the Kenyan clade to background DENV-2 Cosmopolitan data and only offer  
395 estimation of selection pressure across the entire Cosmopolitan lineage (Table 1). Another caveat is  
396 that dengue virus selection pressure analyses are also inherently susceptible to the size and sampling  
397 distribution of the genomic datasets analyzed [7], and our findings here should be compared and  
398 contrasted with other studies sampling dengue viruses in Kenyan and other East African settings,  
399 ideally with similar methods.

400 Among the Kenyan sequence data, linear 9mer peptides which flanked the positively selected amino  
401 acids specific for the Kenyan genomes (Table 2) were not found in any known DENV linear CTL epitopes  
402 documented in IEDB [51]. If the detected positive selection in these positions was indeed due to  
403 population immunologic pressures, this would indicate that there might be yet undiscovered DENV  
404 epitopes and immunogenic regions specific for this part of the world. Interestingly, epitope prediction  
405 analyses showed that one of these lineage-wide positive selection sites resides within a predicted  
406 MHC-I CD8+ DENV-2 Cosmopolitan virus epitope only evident in a sampled Kenyan virus (Table 3),  
407 offering further evidence that there are viral-host interactions unique to DENV-2 viruses circulating in  
408 the Kenyan population. This should be confirmed with further DENV genome sampling, more precise T-  
409 cell epitope prediction using host HLA typing, and in-vitro cell-mediated immunity assays, particularly  
410 as such peptides may be important immunogens of relevance to dengue vaccine design and evaluation  
411 [55].

412 Taken together, our findings indicate that the 2017 Kenyan Malindi DENV-2 outbreak arose from a  
413 strain which had circulated for several years in Kenya before recent detection, has experienced  
414 diversifying selection pressure, and may contain new putative immunogens relevant to vaccine design.

415 While limited by a relatively small number of absolute DENV-2 genomes, this study is an important  
416 step toward redressing our limited understanding of the virology and epidemiology of DENV viruses in  
417 this country, and more broadly in Africa, and should prompt further whole genome sequencing of  
418 dengue viruses in this and other African countries.

419 **Acknowledgements:**

420 The authors are grateful for those research subjects who participated in this study.

421 **Disclaimer:**

422 The views expressed in this article are those of the authors and do not necessarily reflect the official  
423 policy or position of the Department of the Army, Department of Defense nor the U.S. Government.  
424 Several of the authors are US Government Employees. This work was prepared as part of their official  
425 duties. Title 17 U.S.C. § 105 provides that 'Copyright protection under this title is not available for any  
426 work of the United States Government.' Title 17 U.S.C. §101 defines a U.S. Government work as a work  
427 prepared by a military service member or employee of the U.S. Government as part of that person's  
428 official duties

429

430

431

432

433

434

435

436

437

438

439 **Tables and figure legends**

**Table 1. DENV-2 Cosmopolitan lineage codons estimated to be under diversifying (positive) selection pressure\***

Genome	Protein	Statistical significance of positive selection pressure detected			Comments
		FUBAR (probability)	SLAC (p-value)	FEL (p-value)	
171	prM	0.9167	p > 0.1	p = 0.054	Weak evidence for positive selection, codon variation is not unique to Kenyan data.
670	Env	0.9186	p > 0.1	p = 0.041	Moderate evidence for positive selection, codon variation is not unique to Kenyan data.
1867	NS3	0.99	p = 0.03	p = 0.006	Strong evidence of positive selection, found within CD8+ epitope predicted epitope TFDSEYIKT, codon variation not unique to Kenyan data.
2387	NS4B	0.97	p > 0.1	p = 0.016	Moderate evidence for positive selection, codon variation not unique Kenyan data but appears to have driven the diversification of the 2012-2013 DENV-2 Cosmopolitan Singapore outbreak.
2391	NS4B	0.98	p > 0.1	p = 0.049	Moderate evidence for positive selection, codon variation not unique to Kenyan data but appears to have driven the diversification of the 2012-2013 DENV-2 Cosmopolitan Singapore outbreak.

2762	NS5	0.94	$p = 0.04$	$p = 0.038$	Strong evidence for positive selection, codon variation is not unique to Kenyan data.
3135	NS5	0.92	$p > 0.1$	$p = 0.058$	Weak evidence for positive selection, codon variation is not unique to Kenyan data.

---

\*Codons found to be under positive selection by at least two methods only presented. Dataset included an American genotype outgroup strain.

441

442



443

444

**Table 2. Amino acid positions under diversifying selection specific for the Kenyan strains sampled<sup>a</sup>**

Amino acid position	Gene	p-value
430	E	0.006
1243	NS2A	0.036
2269	NS4A	0.028
2334	NS4A	0.002
2660	NS5	0.023
3016	NS5	0.004

<sup>a</sup>Determined by FEL method comparing Kenyan-only data with all non-Kenyan whole genome DENV-2 Cosmopolitan data and a DENV-2 American genotype reference strain.

445

446

**Table 3. MHC-I epitopes predicted in Kenyan DENV-2 whole genome data**

HLA allele	Predicted MHC-I epitope	Protein	Polyprotein position	Conservancy in non-Kenyan data	Conservancy in Kenyan data	Predicted MHC-I affinity (percentile rank IC50) <sup>b</sup>	Published experimental assays associated with predicted linear epitopes
C*0602	FRKEIGRML	Capsid	84 – 92	99%	100%	0.11	Positive proliferation and cytotoxicity assays for DENV 4 (HLA-DR1 and HLA-DPw4) <sup>c</sup>
C*0602	KRHVLGRLI	Env	624 - 623	97%	100%	0.15	–
C*0602	FRDLGRVMV	NS2A	1177 - 1185	98%	100%	0.17	–
C*0401	KMDIGAPLL	NS4A	2329 - 2337	0%	7%	0.13	–
C*0401	TFDSEYIKT	NS3	1864 - 1872	80%	100%	0.15	–
C*0401	GWGNGCGL F	Env	380 - 388	100%	100%	0.16	Positive MHC ligand assay for HLA-A*23:01 (DENV4), HLA-A*24:03 (DENV1) & HLA-A*24:02 (DENV4) <sup>d,e</sup>

A*02:01	FTMRLLSPV	NS3	1740 - 1748	9.6% <sup>a</sup>	100%	0.2
---------	-----------	-----	-------------	-------------------	------	-----

Positive MHC ligand assay for DENV1 and/or DENV2 for HLA-A\*26:01, HLA-A\*02:01, HLA-A\*02:03, HLA-A\*02:06, HLA-A\*02:17, HLA-A\*32:15, HLA-A\*68:02, HLA-B\*15:42, HLA-B\*45:06, HLA-B\*46:01, HLA-B\*83:01, HLA-C\*04:01, HLA-C\*05:01, HLA-C\*08:02 & HLA-C\*14:02<sup>f</sup>

---

<sup>a</sup>Highly conserved in data from India, Sri-Lanka, Pakistan, Saudi Arabia. Rare in data from East/SE Asia

<sup>b</sup>Scores close to zero indicate higher MHC-I affinity. Percentile rank is generated by comparing the peptide's IC50 against those of a set of random peptides from SWISSPROT database

<sup>c</sup>[56]

<sup>d</sup>[57]

<sup>e</sup>[58]

<sup>f</sup>[59]

447

448

449

450

451 **Figure 1.** Whole genome maximum likelihood phylogenetic tree of DENV2 Cosmopolitan genotype. American  
452 genotype outgroup strain (HM582104/American\_Somoa/1972) has been removed for clarity. Numbers indicated  
453 aLRT support for key nodes, with aLRT values  $\geq 0.75$  indicating robust support. Kenyan genomes are noted in  
454 red, Tanzania data is indicated in green, all other countries are represented by black. Some well-supported  
455 clades were collapsed for clarity. Scale bar indicates genetic distance substitutions/site.

456 **Figure 2.** Maximum likelihood phylogeny of African *env* sequence data and reference DENV-2 Cosmopolitan *env*  
457 sequence data. Some background data clades collapsed to improve clarity, and all taxa names are made  
458 available in full with the removed American genotype outgroup in supplemental Figure S2. Data are color-  
459 coded by African country (Kenya = red, Uganda = orange, Burkina Faso = green, Ghana = purple,  
460 Somalia = blue, Tanzania = brown), and all non-African countries are represented by black. Scale bar indicates  
461 genetic distance (substitutions/site).

462 **Figure 3.** Bayesian time-scaled phylogeny of the Cosmopolitan 'East-West' African cluster. The scale represents  
463 time with scale of years. Color legend refers to the geographic location of collection of the sampled viruses (tips)  
464 as well as inferred ancestral strains. Numbers refer to the geographic state probability of nodes

465 **Figure 4.** Bayesian time-scaled phylogeny of the Cosmopolitan sub-lineage containing all Kenya data. Time-scale  
466 not shown. Color legend refers to the geographic location of collection of sampled viruses (tips) as well as  
467 inferred ancestral strains. Numbers refer to the geographic state probability of nodes.

468 **Supporting Information Legends:**

469 **Figure S1.** Neighbor-joining trees on four sub-genomic regions (CDS nucleotide positions 1-2543, 2544-5087,  
470 5088-7630 and 7631-10173). Scale refers to nucleotide substitutions/site.

471 **Figure S2.** Maximum likelihood phylogeny of full DENV-2 Cosmpolitan env genes. American genotype outgroup  
472 removed for clarity. Scale refers to nucleotide substitutions/site. Numbers refer to aLRT values. Taxa tables are  
473 right-aligned for clarity, and are color-coded by African country (Kenya = red, Uganda = orange, Burkina Faso =  
474 green, Ghana = purple, Somalia = blue, Tanzania = brown). All non-African taxa labels are indicated in black.

475 **Supplemental material (extended):** Additional methods, primers, and reference GenBank accession numbers.

## 476 **References**

- 477 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and  
478 burden of dengue. *Nature*. 2013;496:504-7. doi: 10.1038/nature12060. PubMed PMID: 23563266.
- 479 2. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. *The*  
480 *American journal of tropical medicine and hygiene*. 1988;38:172-80. PubMed PMID: 3341519.
- 481 3. Fritzell C, Rousset D, Adde A, Kazanji M, Van Kerkhove MD, Flamand C. Current challenges and  
482 implications for dengue, chikungunya and Zika seroprevalence studies worldwide: A scoping review. *PLoS*  
483 *neglected tropical diseases*. 2018;12:e0006533. doi: 10.1371/journal.pntd.0006533. PubMed PMID: 30011271.
- 484 4. McBride WJ, Mullner H, LaBrooy JT, Wronski I. The 1993 dengue 2 epidemic in North Queensland: a  
485 serosurvey and comparison of hemagglutination inhibition with an ELISA. *The American journal of tropical*  
486 *medicine and hygiene*. 1998;59:457-61. PubMed PMID: 9749644.
- 487 5. Araujo VEMd, Bezerra JMT, Amancio FF, Passos VMdA, Carneiro M. Increase in the burden of dengue in  
488 Brazil and federated units, 2000 and 2015: analysis of the Global Burden of Disease Study 2015. *Revista*  
489 *brasileira de epidemiologia = Brazilian journal of epidemiology*. 2017;20Suppl 01:205-16. doi: 10.1590/1980-  
490 5497201700050017. PubMed PMID: 28658384.
- 491 6. Simmons CP, Farrar JJ, Nguyen vVC, Wills B. Dengue. *The New England journal of medicine*.  
492 2012;366:1423-32. doi: 10.1056/NEJMra1110265. PubMed PMID: 22494122.
- 493 7. Pollett S, Melendrez MC, Maljkovic Berry I, Duchene S, Salje H, Cummings DAT, et al. Understanding  
494 dengue virus evolution to support epidemic surveillance and counter-measure development. *Infection, genetics*  
495 *and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*. 2018;62:279-  
496 95. doi: 10.1016/j.meegid.2018.04.032. PubMed PMID: 29704626.
- 497 8. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of Dengue Serostatus  
498 on Dengue Vaccine Safety and Efficacy. *The New England journal of medicine*. 2018;379:327-40. doi:  
499 10.1056/NEJMoa1800820. PubMed PMID: 29897841.
- 500 9. Baba M, Villinger J, Masiga DK. Repetitive dengue outbreaks in East Africa: A proposed phased  
501 mitigation approach may reduce its impact. *Reviews in medical virology*. 2016;26:183-96. doi:  
502 10.1002/rmv.1877. PubMed PMID: 26922851.
- 503 10. Rigau-Perez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in  
504 Spanish. *The American journal of tropical medicine and hygiene*. 1998;59:272-4. PubMed PMID: 9715945.
- 505 11. Amoako N, Duodu S, Dennis FE, Bonney JHK, Asante KP, Ameh J, et al. Detection of Dengue Virus among  
506 Children with Suspected Malaria, Accra, Ghana. *Emerging infectious diseases*. 2018;24:1544-7. doi:  
507 10.3201/eid2408.180341. PubMed PMID: 30015610.
- 508 12. Weetman D, Kamgang B, Badolo A, Moyes CL, Shearer FM, Coulibaly M, et al. Aedes Mosquitoes and  
509 Aedes-Borne Arboviruses in Africa: Current and Future Threats. *International journal of environmental research*  
510 *and public health*. 2018;15. doi: 10.3390/ijerph15020220. PubMed PMID: 29382107.

- 511 13. Mengesha Tsegaye M, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow  
512 fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC public health*. 2018;18:1011. doi:  
513 10.1186/s12889-018-5726-9. PubMed PMID: 30107830.
- 514 14. Bosa HK MJ, Kimuli I, Lutwama J Dengue fever outbreak in Mogadishu, Somalia 2011: co-circulation of  
515 three dengue virus serotypes. *International Journal of Infectious Diseases* 2014;21(3).
- 516 15. Ferede G, Tiruneh M, Abate E, Wondimeneh Y, Damtie D, Gadisa E, et al. A serologic study of dengue in  
517 northwest Ethiopia: Suggesting preventive and control measures. *PLoS neglected tropical diseases*.  
518 2018;12:e0006430. doi: 10.1371/journal.pntd.0006430. PubMed PMID: 29852020.
- 519 16. Braack L, Gouveia de Almeida AP, Cornel AJ, Swanepoel R, de Jager C. Mosquito-borne arboviruses of  
520 African origin: review of key viruses and vectors. *Parasites & vectors*. 2018;11:29. doi: 10.1186/s13071-017-  
521 2559-9. PubMed PMID: 29316963.
- 522 17. Oludele J, Lesko B, Mahumane Gundane I, de Bruycker-Nogueira F, Muianga A, Ali S, et al. Dengue Virus  
523 Serotype 2 Established in Northern Mozambique (2015-2016). *The American journal of tropical medicine and*  
524 *hygiene*. 2017;97:1418-22. doi: 10.4269/ajtmh.17-0317. PubMed PMID: 29016312.
- 525 18. Ward T, Samuel M, Maoz D, Runge-Ranzinger S, Boyce R, Toledo J, et al. Dengue data and surveillance in  
526 Tanzania: a systematic literature review. *Tropical medicine & international health : TM & IH*. 2017;22:960-70.  
527 doi: 10.1111/tmi.12903. PubMed PMID: 28556417.
- 528 19. Gathii K, Nyataya JN, Mutai BK, Awinda G, Waitumbi JN. Complete Coding Sequences of Dengue Virus  
529 Type 2 Strains from Febrile Patients Seen in Malindi District Hospital, Kenya, during the 2017 Dengue Fever  
530 Outbreak. *Genome announcements*. 2018;6. doi: 10.1128/genomeA.00076-18. PubMed PMID: 29650565.
- 531 20. Johnson BK, Ocheng D, Gichogo A, Okiro M, Libondo D, Kinyanjui P, et al. Epidemic dengue fever caused  
532 by dengue type 2 virus in Kenya: preliminary results of human virological and serological studies. *East African*  
533 *medical journal*. 1982;59:781-4. PubMed PMID: 7184757.
- 534 21. Obonyo M, Fidhow A, Ofula V. Investigation of laboratory confirmed Dengue outbreak in North-eastern  
535 Kenya, 2011. *PloS one*. 2018;13:e0198556. doi: 10.1371/journal.pone.0198556. PubMed PMID: 29879159.
- 536 22. Ellis EM, Neatherlin JC, Delorey M, Ochieng M, Mohamed AH, Mogeni DO, et al. A household serosurvey  
537 to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. *PLoS neglected tropical diseases*.  
538 2015;9:e0003733. doi: 10.1371/journal.pntd.0003733. PubMed PMID: 25923210.
- 539 23. Konongoi L, Ofula V, Nyunja A, Owaka S, Koka H, Makio A, et al. Detection of dengue virus serotypes 1, 2  
540 and 3 in selected regions of Kenya: 2011-2014. *Virology journal*. 2016;13:182. doi: 10.1186/s12985-016-0641-0.  
541 PubMed PMID: 27814732.
- 542 24. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al. Unrecognized Dengue Virus  
543 Infections in Children, Western Kenya, 2014-2015. *Emerging infectious diseases*. 2017;23:1915-7. doi:  
544 10.3201/eid2311.170807. PubMed PMID: 29048283.
- 545 25. Vu DM, Banda T, Teng CY, Heimbaugh C, Muchiri EM, Mungai PL, et al. Dengue and West Nile Virus  
546 Transmission in Children and Adults in Coastal Kenya. *The American journal of tropical medicine and hygiene*.  
547 2017;96:141-3. doi: 10.4269/ajtmh.16-0562. PubMed PMID: 27821697.
- 548 26. Grossi-Soyster EN, Cook EAJ, de Glanville WA, Thomas LF, Krystosik AR, Lee J, et al. Serological and  
549 spatial analysis of alphavirus and flavivirus prevalence and risk factors in a rural community in western Kenya.  
550 *PLoS neglected tropical diseases*. 2017;11:e0005998. doi: 10.1371/journal.pntd.0005998. PubMed PMID:  
551 29040262.
- 552 27. Chepkorir E, Venter M, Lutomiah J, Mulwa F, Arum S, Tchouassi DP, et al. The occurrence, diversity and  
553 blood feeding patterns of potential vectors of dengue and yellow fever in Kacheliba, West Pokot County, Kenya.  
554 *Acta tropica*. 2018;186:50-7. doi: 10.1016/j.actatropica.2018.07.008. PubMed PMID: 30006028.
- 555 28. Agha SB, Tchouassi DP, Bastos ADS, Sang R. Assessment of risk of dengue and yellow fever virus  
556 transmission in three major Kenyan cities based on *Stegomyia* indices. *PLoS neglected tropical diseases*.  
557 2017;11:e0005858. doi: 10.1371/journal.pntd.0005858. PubMed PMID: 28817563.

- 558 29. Ndenga BA, Mutuku FM, Ngugi HN, Mbakaya JO, Aswani P, Musunzaji PS, et al. Characteristics of *Aedes*  
559 *aegypti* adult mosquitoes in rural and urban areas of western and coastal Kenya. *PloS one*. 2017;12:e0189971.  
560 doi: 10.1371/journal.pone.0189971. PubMed PMID: 29261766.
- 561 30. Bett B, Said MY, Sang R, Bukachi S, Wanyoike S, Kifugo SC, et al. Effects of flood irrigation on the risk of  
562 selected zoonotic pathogens in an arid and semi-arid area in the eastern Kenya. *PloS one*. 2017;12:e0172626.  
563 doi: 10.1371/journal.pone.0172626. PubMed PMID: 28562600.
- 564 31. Pollett S, Maljkovic-Berry I, Melendrez MC, Jarman RG. Genotype mapping of dengue viruses over 70  
565 years reveals continental-scale spatial structure of major lineages and identifies at-risk genotype-naïve regions  
566 (Scientific Poster). *Cell Emerging Viruses Symposium*, 2017, Arlington, VA.
- 567 32. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical,  
568 industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. *Vaccine*. 2011;29:7229-41.  
569 doi: 10.1016/j.vaccine.2011.06.094. PubMed PMID: 21745521.
- 570 33. Arredondo-Garcia JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, et  
571 al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and  
572 Latin America. *Clinical microbiology and infection : the official publication of the European Society of Clinical*  
573 *Microbiology and Infectious Diseases*. 2018;24:755-63. doi: 10.1016/j.cmi.2018.01.018. PubMed PMID:  
574 29408333.
- 575 34. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al.  
576 Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. *The New England journal of*  
577 *medicine*. 2015;373:1195-206. doi: 10.1056/NEJMoa1506223. PubMed PMID: 26214039.
- 578 35. [https://www.opendata.go.ke/Population/2009-Census-Vol-1-Table-3-Rural-and-Urban-Populati/e7c7-](https://www.opendata.go.ke/Population/2009-Census-Vol-1-Table-3-Rural-and-Urban-Populati/e7c7-w67t/1)  
579 [w67t/1](https://www.opendata.go.ke/Population/2009-Census-Vol-1-Table-3-Rural-and-Urban-Populati/e7c7-w67t/1) accessed Feb 01 2019.
- 580 36. Djikeng A, Halpin R, Kuzmickas R, Depasse J, Feldblyum J, Sengamalay N, Afonso C, Zhang X, Anderson  
581 NG, Ghedin E, Spiro DJ. 2008. Viral genome sequencing by random priming methods. *BMC Genomics* 9:5–9.  
582 doi:10.1186/1471-2164-9-5.
- 583 37. [https://github.com/VDBWRAIR/ngs\\_mapper](https://github.com/VDBWRAIR/ngs_mapper) accessed Feb 1 2019.
- 584 38. <https://www.viprbrc.org>
- 585 39. <https://www.ncbi.nlm.nih.gov/genbank/>.
- 586 40. Nakamura T, Yamada KD, Tomii K, Katoh K. Parallelization of MAFFT for large-scale multiple sequence  
587 alignments. *Bioinformatics (Oxford, England)*. 2018;34:2490-2. doi: 10.1093/bioinformatics/bty121. PubMed  
588 PMID: 29506019.
- 589 41. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger  
590 Datasets. *Molecular biology and evolution*. 2016;33(7):1870-4. Epub 2016/03/24. doi: 10.1093/molbev/msw054.  
591 PubMed PMID: 27004904.
- 592 42. Martin DP, Murrell B, Khoosal A, Muhire B. Detecting and Analyzing Genetic Recombination Using RDP4.  
593 *Methods in molecular biology (Clifton, NJ)*. 2017;1525:433-60. doi: 10.1007/978-1-4939-6622-6\_17. PubMed  
594 PMID: 27896731.
- 595 43. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to  
596 estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Systematic biology*.  
597 2010;59:307-21. doi: 10.1093/sysbio/syq010. PubMed PMID: 20525638.
- 598 44. jModelTest 2: more models, new heuristics and parallel computing., (2012).
- 599 45. Drummond AJ, Suchard MA, Xie D, Rambaut A. Bayesian phylogenetics with BEAUti and the BEAST 1.7.  
600 *Molecular biology and evolution*. 2012;29:1969-73. doi: 10.1093/molbev/mss075. PubMed PMID: 22367748.
- 601 46. Pond SLK, Frost SDW, Muse SV. HyPhy: hypothesis testing using phylogenies. *Bioinformatics (Oxford,*  
602 *England)*. 2005;21:676-9. doi: 10.1093/bioinformatics/bti079. PubMed PMID: 15509596.
- 603 47. <https://www.datamonkey.org/>, accessed Feb 06 2019.
- 604 48. <http://www.allelefrequencies.net/> access Jan 2019.

- 605 49. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated  
606 classification. *BMC Immunol.* 2008;9:1. Epub 2008/01/24. doi: 10.1186/1471-2172-9-1. PubMed PMID:  
607 18211710; PubMed Central PMCID: PMCPMC2245908.
- 608 50. <http://tools.iedb.org/mhci/> accessed Feb 06 2019.
- 609 51. <https://www.iedb.org/>
- 610 52. Monamele GC, Demanou M. First documented evidence of dengue and malaria co-infection in children  
611 attending two health centers in Yaounde, Cameroon. *The Pan African medical journal.* 2018;29:227. doi:  
612 10.11604/pamj.2018.29.227.15316. PubMed PMID: 30100980.
- 613 53. Schreiber MJ, Holmes EC, Ong SH, Soh HSH, Liu W, Tanner L, et al. Genomic epidemiology of a dengue  
614 virus epidemic in urban Singapore. *Journal of virology.* 2009;83:4163-73. doi: 10.1128/JVI.02445-08. PubMed  
615 PMID: 19211734.
- 616 54. Jarman RG, Melendrez MC, Maljkovic Berry I, Pollett S, Li T, Vallard TG, Klungthong C; Nisalak A,  
617 Thaisomboonsuk B, Macareo L, Rothman A, Yoon IK, Thomas SJ, Endy T. Diversity and circulation of dengue  
618 virus serotypes 1 - 4 among sub-districts in Kamphaeng Phet, Thailand from 2010 to 2012: implications for  
619 surveillance and control (Scientific Poster). *Epidemics*, 2017, Sitges. Spain.
- 620 55. Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, et al. Global Assessment of Dengue  
621 Virus-Specific CD4(+) T Cell Responses in Dengue-Endemic Areas. *Frontiers in immunology.* 2017;8:1309. doi:  
622 10.3389/fimmu.2017.01309. PubMed PMID: 29081779.
- 623 56. Gagnon SJ, Zeng W, Kurane I, Ennis FA. Identification of two epitopes on the dengue 4 virus capsid  
624 protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-  
625 lymphocyte clones. *Journal of virology.* 1996;70(1):141-7. Epub 1996/01/01. PubMed PMID: 8523518; PubMed  
626 Central PMCID: PMCPMC189798.
- 627 57. Lund O, Nascimento EJ, Maciel M, Jr., Nielsen M, Larsen MV, Lundegaard C, et al. Human leukocyte  
628 antigen (HLA) class I restricted epitope discovery in yellow fever and dengue viruses: importance of HLA binding  
629 strength. *PloS one.* 2011;6(10):e26494. Epub 2011/11/01. doi: 10.1371/journal.pone.0026494. PubMed PMID:  
630 22039500; PubMed Central PMCID: PMCPMC3198402.
- 631 58. <https://www.iedb.org/reference/1022588>.
- 632 59. <https://www.iedb.org/epitope/124151>.

633










Figure 3




Figure 4